Clinical Trial Update: A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide [Phase 2]

View source ↗

Summary

Phase 2 double-blind study evaluating intranasal esketamine for rapid reduction of depressive symptoms and suicidal ideation in adults with major depressive dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Esketamine (esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-04-24